

Nikolai Z Zhelev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4880004/publications.pdf>

Version: 2024-02-01

43
papers

1,224
citations

567144

15
h-index

377752

34
g-index

51
all docs

51
docs citations

51
times ranked

1656
citing authors

#	ARTICLE	IF	CITATIONS
1	In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). <i>International Journal of Cancer</i> , 2002, 102, 463-468.	2.3	371
2	Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin. <i>Chemical Biology and Drug Design</i> , 2000, 55, 163-172.	1.2	146
3	Bioluminescent imaging of Cdk2 inhibition in vivo. <i>Nature Medicine</i> , 2004, 10, 643-648.	15.2	91
4	New Lupane Derived Compounds with Pro-Apoptotic Activity in Cancer Cells: Synthesis and Structure-Activity Relationships. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 5402-5415.	2.9	83
5	A Quantitative Study of the in Vitro Binding of the C-Terminal Domain of p21 to PCNA: Affinity, Stoichiometry, and Thermodynamics. <i>Biochemistry</i> , 2000, 39, 7388-7397.	1.2	78
6	Highly potent p21WAF1 -derived peptide inhibitors of CDK-mediated pRb phosphorylation: Delineation and structural insight into their interactions with cyclin A. <i>Chemical Biology and Drug Design</i> , 2002, 60, 257-270.	1.2	53
7	Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance. <i>Journal of Biotechnology</i> , 2015, 202, 40-49.	1.9	50
8	Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, boheminine. <i>Electrophoresis</i> , 2000, 21, 3757-3764.	1.3	48
9	The role of modelling in identifying drug targets for diseases of the cell cycle. <i>Journal of the Royal Society Interface</i> , 2006, 3, 617-627.	1.5	29
10	Monoclonal antibody against a nuclear matrix antigen in proliferating human cells. <i>Biology of the Cell</i> , 1987, 60, 1-8.	0.7	25
11	Pharmacological inhibition of ATM by KU55933 stimulates ATM transcription. <i>Experimental Biology and Medicine</i> , 2012, 237, 622-634.	1.1	20
12	Effects of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) on the physiology of cultured human keratinocytes. <i>Biochemical Pharmacology</i> , 2005, 70, 824-836.	2.0	19
13	Effect of salinity on the synthesis of ribulose-1,5-bisphosphate carboxylase/oxygenase in barley leaves. <i>Journal of Plant Physiology</i> , 1992, 140, 46-51.	1.6	18
14	Synthesis and biological activity of conjugates between paclitaxel and the cell delivery vector penetratin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 2628-2631.	1.0	16
15	What is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer?. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 149-159.	1.5	16
16	Effect of liquid nitrogen pre-treatment on various types of wool waste fibres for biogas production. <i>Heliyon</i> , 2018, 4, e00619.	1.4	14
17	Role of Membrane Lipids in the Regulation of Erythrocytic Oxygen-Transport Function in Cardiovascular Diseases. <i>BioMed Research International</i> , 2016, 2016, 1-11.	0.9	12
18	Nothing in Excess - Lessons Learned from the Expression of High-Mobility Group Proteins Type a in Non-Cancer and Cancer Cells. <i>Biotechnology and Biotechnological Equipment</i> , 2011, 25, 2572-2575.	0.5	11

#	ARTICLE	IF	CITATIONS
19	The D153del Mutation in GNB3 Gene Causes Tissue Specific Signalling Patterns and an Abnormal Renal Morphology in Rge Chickens. PLoS ONE, 2011, 6, e21156.	1.1	11
20	Use of reversed-phase high-performance liquid chromatography on polystyrene-divinylbenzene columns for the rapid separation and purification of acid-soluble nuclear proteins. Journal of Chromatography A, 1997, 763, 65-70.	1.8	10
21	Cytoprotective Effects of Dinitrosyl Iron Complexes on Viability of Human Fibroblasts and Cardiomyocytes. Frontiers in Pharmacology, 2019, 10, 1277.	1.6	10
22	Cancer research and personalised medicine: a new approach to modelling time-series data using analytical methods and Half systems. Current Opinion in Biotechnology, 2011, 22, S59.	3.3	9
23	Novel insights of Ataxia Telangiectasia Mutated (ATM) regulation and its potential as a target for therapeutic intervention in cancer. Current Opinion in Biotechnology, 2011, 22, S115-S116.	3.3	8
24	The small Rho GTPase Rac1 controls normal human dermal fibroblasts proliferation with phosphorylation of the oncoprotein c-myc. Biochemical and Biophysical Research Communications, 2007, 359, 834-839.	1.0	7
25	Monoclonal antibody to a nucleolar antigen of human B-lymphoblastoid cells. Cell Biology International Reports, 1987, 11, 181-187.	0.7	6
26	Signalling to chromatin and the superinduction of proto-oncogenes. Biochemical Society Transactions, 1993, 21, 907-912.	1.6	6
27	Repair, Abort, Ignore? Strategies for Dealing With UV Damage. Biotechnology and Biotechnological Equipment, 2011, 25, 2443-2446.	0.5	6
28	Differential Genetic Advantages in Youth and in Aging, or How to Die Healthy. Biotechnology and Biotechnological Equipment, 2012, 26, 2703-2711.	0.5	6
29	Physical and Chemical Processes and the Morphofunctional Characteristics of Human Erythrocytes in Hyperglycaemia. Frontiers in Physiology, 2017, 8, 606.	1.3	5
30	The effect of experimental hyperoxia on erythrocytes' oxygen-transport function. Biotechnology and Biotechnological Equipment, 2018, 32, 1236-1250.	0.5	4
31	Effects of the CDK-inhibitor CYC202 on p38 MAPK, ERK1/2 and c-Myc activities in papillomavirus type 16 E6- and E7-transformed human keratinocytes. Oncology Reports, 2007, 18, 999-1005.	1.2	4
32	Alterations in Protein P53 Expression During the Development of Pressure Overload-Induced Left Ventricular Hypertrophy in Rats. Biotechnology and Biotechnological Equipment, 2008, 22, 977-983.	0.5	2
33	Some problems and errors in cytogenetic biodosimetry. Biotechnology and Biotechnological Equipment, 2017, 31, 460-468.	0.5	2
34	Individual capacity for repair of DNA damage and potential uses of stem cell lines for clinical applications: a matter of (genomic) integrity. Biotechnology and Biotechnological Equipment, 2018, 32, 1352-1358.	0.5	2
35	Prospects for Radiopharmaceuticals as Effective and Safe Therapeutics in Oncology and Challenges of Tumor Resistance to Radiotherapy. Dose-Response, 2021, 19, 155932582199366.	0.7	2
36	Implementation of light-scattering instrumentation: innovation, design and development. , 2012, , 1-45.		1

#	ARTICLE	IF	CITATIONS
37	Time course and progression of pressure overload-induced cardiac hypertrophy in rats. <i>Folia Medica</i> , 2005, 47, 52-7.	0.2	1
38	In Vivo Assessment of Left Ventricular Hypertrophy in Rats: Necropsy Validation. <i>Biotechnology and Biotechnological Equipment</i> , 2006, 20, 124-132.	0.5	0
39	The "Golden Age" of Biotechnology in Europe. <i>Biotechnology and Biotechnological Equipment</i> , 2011, 25, 2688-2688.	0.5	0
40	You Cannot Always Win: Molecular Bases of the Resistance of Picornaviruses to Win Compounds. <i>Biotechnology and Biotechnological Equipment</i> , 2012, 26, 2826-2828.	0.5	0
41	New Approaches to Rapid Screening for Protein Aggregates by Light Scattering. <i>Biotechnology and Biotechnological Equipment</i> , 2013, 27, 4327-4331.	0.5	0
42	Effects of the CDK-inhibitor CYC202 on p38 MAPK, ERK1/2 and c-Myc activities in papillomavirus type 16 E6- and E7-transformed human keratinocytes. <i>Oncology Reports</i> , 0, , .	1.2	0
43	Splicing mutation in gene leading to exon skipping and Barth syndrome. <i>Acta Myologica</i> , 2021, 40, 88-92.	1.5	0